Safety and pharmacokinetics of oral lansoprazole in preadolescent rats exposed from weaning through sexual maturity.

[1]  C. Dupont,et al.  Pharmacokinetic‐pharmacodynamic study of oral lansoprazole in children , 2002, Clinical pharmacology and therapeutics.

[2]  D. Hattis,et al.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  L. Michaud,et al.  Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis , 2001, Alimentary pharmacology & therapeutics.

[4]  V. Tolia,et al.  Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan , 2000, The Pediatric infectious disease journal.

[5]  G. Salvia,et al.  Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[6]  R. Rabah,et al.  A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. , 2000, Journal of pediatric gastroenterology and nutrition.

[7]  J. Reilly,et al.  Safety profile of the proton-pump inhibitors. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  C. Pelatan,et al.  Inhibiteurs de la pompe à protons en pédiatrie , 1999 .

[9]  K. Takeuchi,et al.  Effects of pantoprazole, a novel H+/K+‐ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole , 1999, Journal of gastroenterology and hepatology.

[10]  B. Bilir,et al.  Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole , 1999, Human & experimental toxicology.

[11]  J. Freston,et al.  Safety Profile of Lansoprazole , 1999, Drug safety.

[12]  K. Yasuda,et al.  Pharmacokinetics:Pharmacokinetic Differences Between Lansoprazole Enantiomers in Rats , 1998 .

[13]  G. L. Kedderis,et al.  Sex-dependent metabolism of xenobiotics. , 1998, Drug metabolism reviews.

[14]  T. Cresteil,et al.  Delayed ontogenesis of CYP1A2 in the human liver. , 1998, European journal of biochemistry.

[15]  A. Boobis,et al.  Expression and inducibility of P450 enzymes during liver ontogeny , 1997, Microscopy research and technique.

[16]  O. Okazaki,et al.  An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors. , 1997, Chemico-biological interactions.

[17]  H. Leufkens,et al.  A prospective follow‐up study of 5669 users of lansoprazole in daily practice , 1997, Alimentary pharmacology & therapeutics.

[18]  H. Hakusui,et al.  Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[19]  L. Nikonova,et al.  Properties of some nuclear nucleases of rat thymocytes and their changes in radiation-induced apoptosis. , 1993, European journal of biochemistry.

[20]  D. Faulds,et al.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.

[21]  H. Satoh,et al.  Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[22]  S. Thorgeirsson,et al.  Ontogenetic expression of polycyclic aromatic compound-inducible monooxygenase activities and forms of cytochrome P-450 in rabbit. Evidence for temporal control and organ specificity of two genetic regulatory systems. , 1977, The Journal of biological chemistry.

[23]  Vernier Vg,et al.  The bioassay of kanamycin auditory toxicity. , 1968 .

[24]  B. L. Welch.  THE SIGNIFICANCE OF THE DIFFERENCE BETWEEN TWO MEANS WHEN THE POPULATION VARIANCES ARE UNEQUAL , 1938 .

[25]  M. Hollinger,et al.  CRC handbook of toxicology , 1995 .

[26]  D. Faulds,et al.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.

[27]  S. Thorgeirsson,et al.  Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals. , 1979, Biochemical pharmacology.

[28]  John Doull,et al.  VIRAL DISEASES: A SYMPOSIUM , 1976, The Ulster Medical Journal.

[29]  D. Kinden,et al.  Fetal and neonatal development of the microsomal monooxygenase system. , 1976, Drug metabolism reviews.